Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill – Reuters

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via REUTERS
BENGALURU, Jan 4 (Reuters) – Indian drugmaker Dr Reddy's Laboratories Ltd (REDY.NS) will launch its generic version of Merck's (MRK.N) antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday.
The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700.
"Molflu is expected to be available from early next week in pharmacies throughout (India) with particular focus on states with high caseload of COVID-19," the company spokesperson said.
India last week gave emergency use approval to molnupiravir along with two vaccines, as the country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant. read more
The South Asian nation reported 37,379 new COVID-19 cases on Tuesday, its highest since early September. read more
With a view to turn India into a manufacturing hub, Merck has entered into licensing agreements with eight domestic drugmakers, including Dr Reddy's, to make and supply generic versions of molnupiravir to over 100 low- and middle- income countries.
A total of 13 companies in India will make molnupiravir, the country's health minister said last week.
Governments around the world have been scrambling to buy a similar but more effective antiviral treatment from Pfizer (PFE.N), while Merck's pill has faced some setbacks after disappointing trial data. read more
($1 = 74.5800 Indian rupees)
Our Standards: The Thomson Reuters Trust Principles.
Keep up with the latest medical breakthroughs, healthcare trends, pharmaceutical news and more.
Subscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source

Leave a Comment

Your email address will not be published.

Shopping Cart